Drug Profile


Alternative Names: D 2024; levoverapamil

Latest Information Update: 24 Sep 2007

Price : $50

At a glance

  • Originator Celltech R&D
  • Class Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Arrhythmias; Coronary disorders; Hypertension

Most Recent Events

  • 08 Oct 2001 No-Development-Reported for Hypertension in United Kingdom (IV,Infusion)
  • 08 Oct 2001 No-Development-Reported for Coronary disorders in United Kingdom (Unknown route)
  • 08 Oct 2001 No-Development-Reported for Arrhythmias in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top